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Prostate-specific antigen (PSA) is a glycoprotein produced by
the prostate gland to liquify semen, and low concentrations are
normally detected in male serum. Measurement of PSA in serum is
widely used as a tumour marker in the diagnosis and monitoring of
prostate cancer. Immunoreactive prostate-specific antigen (IR-
PSA) has also been detected in other tissues including normal
breast, breast cancer (BC) and benign breast disease (BBD) using
immunofluorometric (Diamandis et al, 1994; Yu et al, 1995a; Yu
et al, 1996) and immunohistochemical techniques (Howarth et al,
1997). A high IR-PSA content has been associated with early
disease stage (Yu et al, 1996), small tumours (Yu et al, 1995a; Yu
et al, 1998) and oestrogen and/or progesterone receptor-positive
breast tumours (Diamandis et al, 1994). Major expression of PSA
has also been detected in BBD tissue (Yu et al, 1996). IR-PSA-
positivity has been suggested as a favourable prognostic indicator
for women with BC (Yu et al, 1995a; Yu et al, 1998) and a marker
of steroid hormone action in normal and diseased female breast
(Yu et al, 1996).
Sera from healthy women contain small amounts of PSA
that is mostly complexed with a1-antichymotrypsin (PSA-ACT)
(Diamandis et al, 1996; Melegos and Diamandis, 1996). About
half of the patients with BC and BBD have been reported to have
free PSA as the major molecular form in their serum (Borchert et
al, 1997a; Melegos and Diamandis, 1996). Giai et al (1995) have
reported that serum PSA in women with BC was not associated
with tumour PSA levels and that for women ³50 years, there was
no difference in serum PSA between normal and BC patients.
Recently, Borchert et al (1997b) reported that serum total PSA
levels in patients with ductal carcinoma in situ are higher than in
patients with ductal carcinoma or other types of breast carcinoma.
It is also higher in serum of patients with poorly differentiated
carcinomas (grade 3) compared with grade 1 or 2 tumours
(Borchert et al, 1997b). Women with BBD seemed to have signifi-
cantly higher serum total PSA levels than female blood donors or
cancer patients (Borchert et al, 1997b).
Exceptionally high serum PSA levels have been observed in
subjects with fibroadenomas and breast cysts (Borchert et al,
1997a). These findings suggest that high serum levels of PSA in
women might be a valuable diagnostic and prognostic marker for
BC, fibroadenomas and breast cysts (Borchert et al, 1997a;
Melegos and Diamandis, 1996; Yu et al, 1995a). In this study we
have evaluated the measurement of serum PSA as a potential test
for differentiating between healthy women and those with BC or
BBD.
MATERIALS AND METHODS
Serum samples
The Kuopio Breast Cancer Study is a prospective, still ongoing
case–control study with the participation of 2500 women. From
these subjects, 90 women with histologically confirmed BC
without any other malignancy, 94 women with BBD and 100
healthy women (population controls) were randomly selected for
the present study. Table 1 shows the clinical data that were
collected from the patient files. Patients with BBD consisted of 47
patients with mastopathy (including 38 women with fibrocystic
disease, 6 women with lipoma, 2 women with periductal mastitis
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Correspondence to: I Mononenand 1 woman with fat necrosis), 44 patients with fibroadenoma,
and two patients with adenoma and one patient with papillo-
matosis. The population controls were matched with the BC
patients for age (± 5 years) and long-term place of residence (rural
vs. urban). All the blood samples were collected by venipuncture
and, after separation, the sera were stored frozen (– 20°C) until
analysed. The serum samples from patients with BC or BBD were
obtained prior to any surgical or other therapeutic procedures. All
the procedures were in accordance with the Helsinki Declaration
of 1975, as revised in 1983, and all the study subjects had signed
an informed consent form.
PSA immunoassay
The total PSA concentrations in sera were measured with an
IMMULITE Third Generation PSA chemiluminescent
immunoassay system (Diagnostic Products Corporation, Los
Angeles, CA, cat. no. LKUP1). The lower detection limit of the
total PSA assay, defined as the concentration two standard devia-
tions above the response at zero dose, is 3 ng l–1 and the functional
sensitivity (coefficient of variation less than 20%) was 5 ng l–1
(DPC Immulite Third Generation PSA product profile). The PSA
method does not crossreact with AFP, CEA, ferritin, hCG, lact-
albumin, prostatic acid phosphatase or prolactin (DPC Immulite
Third Generation PSA product profile).
Statistics
The Kruskal–Wallis one-way variance analysis was used for
median comparisons of total PSA values between patient groups.
The differences between groups in contingency tables were tested
by Fisher exact test. Effect of menopause and age on PSA values
were tested with Spearman correlation analysis. The Pearson
correlation analysis was used to test the effect of age on log (total
PSA) values.
RESULTS
Prostate-specific antigen in serum of breast cancer and
benign breast disease patients
Table 2 shows the distribution of total PSA values in serum of the
healthy controls and patients with BBD or BC. No statistically
significant differences were found between the groups (P > 0.05).
Four per cent of the healthy controls, 3.2% of the BBD patients
and 5.6% of the BC patients had total PSA values over 30 ng l–1;
but these differences were not statistically significant (P > 0.05).
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Table 1 Characteristics of the healthy population control (Co), benign breast disease (BBD) and breast cancer (BC) groups
Panel A Co BBD BC
Number 100 94 90
Mean age (range) 55.2 (32–77) 41.8 (16–75) 59.6 (31–89)
Post-menopausal, number (%) 59 (59.0) 22 (23.4) 62 (68.9)
ERTa, number (%) 18 (18.0) 17 (18.1) 19 (21.1)
BBD diagnosis, number (%)
Mastopathy (M) 47 (50.0)
Fibroadenoma (F) 44 (46.8)
Other (O) 3 (3.2)
BC diagnosis, number (%)
Ductal carcinoma (DC) 56 (62.2)
Lobular carcinoma (LC) 13 (14.4)
Ductal carcinoma in situ (DCIS) 15 (16.7)
Lobular carcinoma in situ (LCIS) 2 (2.2)
Other (O) 4 (4.4)
BC stage, number (%)
Ca in situ 17 (18.9)
I 18 (20.0)
II 19 (21.1)
III 24 (26.7)
IV 12 (13.3)
Invasive BC histological grade, number (%)
I 14 (19.2)
II 38 (52.1)
III 19 (26.0)
Not available 2 (2.7)
aERT = oestrogen replacement therapy.
Table 2 Distribution of total PSA in controls (Co), benign breast disease
(BBD) and breast cancer (BC) patients
Percentile of total PSA (ng l–1)
Patient group N 0 5 25 50 75 95 100
Co 100 3.0 3.0 3.0 4.0 7.0 24.0 83.0
BBD 94 3.0 3.0 4.0 5.0 10.0 21.0 > 20 000
BC 90 3.0 3.0 3.0 5.0 8.0 40.0 422.0Effect of menopause and age on PSA values
Total serum PSA level in pre- and post-menopausal women is
shown in Figure 1. In the control group, but not in the BBD or BC
patients, the PSA level was significantly higher in premenopausal
women than in post-menopausal counterparts (P < 0.01). A signif-
icant negative correlation between total PSA and increasing age
was found in the control group (Spearman’s rho = – 0.31;
P < 0.005) and BC patient group (Spearman’s rho = – 0.42;
P < 0.001), but not in the BBD group (Spearman’s rho = – 0.016;
P > 0.05). The same phenomenon was observed between log (total
PSA) and increasing age in the control group (Pearson’s correla-
tion coefficient = – 0.23; P < 0.05) and BC patient group
(Pearson’s correlation coefficient = – 0.32; P < 0.005), but not
in the BBD group (Pearson’s correlation coefficient = 0.00;
P > 0.05).
Correlation of clinical data with serum PSA values
Table 3 shows the clinical data on those three BBD patients, six
BC patients and five controls who had serum total PSA values
> 24 ng l–1. High total PSA bore no relationship to the clinical
status of the BC patients (Table 3).
Patients with ductal carcinoma tend to have serum total PSA
levels higher than patients with ductal carcinoma in situ (Figure
2A), but the difference was not statistically significant. There was
not any significant correlation or differences between total PSA
values and histological grade (Figure 2B) or disease stage (Figure
2C) of BC.
In BBD, all the 47 patients with mastopathy had their serum
total PSA concentration (median = 5 ng l–1; the interquartile range
= 4–9 ng l–1; 95th percentile = 16 ng l–1) within the 95th percentile
of the values of healthy women. The median of total PSA values in
the patients with fibroadenomas (n = 44) was also 5 ng l–1 (the
interquartile range 3–11 ng l–1), but in 3/44 patients the serum total
PSA concentration was above the 95th percentile of the values of
healthy controls (24 ng l–1) ranging from 80 ng l–1 to more than
20 000 ng l–1 (Table 3).
DISCUSSION
Earlier reports have suggested that IR-PSA-positivity of breast
tumours is a favourable prognostic indicator for women with BC
(Giai et al, 1995; Yu et al, 1995a, 1998) and that high serum levels
of PSA in women might represent a valuable diagnostic marker in
BC (Borchert et al, 1997b; Melegos and Diamandis, 1996) as well
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Figure 1 Concentration of total PSA in serum of pre- (Pre) and post-
menopausal (Post) healthy women (Co; n = 100), female patients with BBD
(n = 94) and women with BC (n = 90). Boxplots show the median,
interquartile range, and minimum and maximum values in each group. Total
PSA level in the control group was significantly higher in premenopausal
women than in post-menopausal subjects (P < 0.01)
1
10
100
1000
T
o
t
a
l
 
P
S
A
 
(
n
g
 
l
–
1
)
DC
n = 56
LC
n = 13
DCIS
n = 15
LCIS
n = 2
O
n = 4
1
10
100
1000
T
o
t
a
l
 
P
S
A
 
(
n
g
 
l
–
1
)
I
n = 14
I
n = 38
III
n = 19
NA
n = 2
BC diagnosis
Histological grade
1
10
100
1000
T
o
t
a
l
 
P
S
A
 
(
n
g
 
l
–
1
)
CaIS
n = 17
I
n = 18
II
n = 19
III
n = 24
IV
n = 12
BC stage
A
C
C
DC
n = 56
LC
n = 13
DCIS
n = 15
LCIS
n = 2
O
n = 4
I
n = 14
II
n = 38
III
n = 19
NA
n = 2
Histological grade
BC Diagnosis
Figure 2 Total PSA levels in the serum of BC patients with different
histological types (A), histological grades (B), and stages of BC (C). Patients
with ductal carcinoma tend to have serum total PSA levels higher than those
with ductal carcinoma in situ, although the difference was not significant
(P > 0.05). Total PSA levels did not reveal any significant differences
between different histological grades or different stages of BC. Abbreviations
as in Table 1; NA = not analysedas fibroadenomas and breast cysts (Borchert et al, 1997a; Borchert
et al, 1997b). However, discordant data concerning the clinical
significance of PSA immunoreactivity in breast tumour cytosols
(Astill et al, 1996; Dibbelt et al, 1996; Wu et al, 1995) and in
breast cysts (Filella et al, 1996; Lai et al, 1996; Mannello et al,
1996) as well as the diagnostic value of serum total PSA in BC
(Giai et al, 1995) and breast cyst disease (Filella et al, 1996) have
been presented. Most of the earlier results have been obtained
using a time-resolved immunofluorometric (TR-FIA) PSA assay
(Borchert et al, 1997b; Diamandis et al, 1994; Ferguson et al,
1996; Melegos and Diamandis, 1996; Yu et al, 1995a, 1996, 1998)
which is not commercially available. In this study we have used a
commercially available ultrasensitive chemiluminescent enzyme
immunoassay system that has been shown to have sensitivity and
specificity very close to those of the TR-FIA method (Ferguson et
al, 1996; Witherspoon and Lapeyrolerie, 1997) and to detect reli-
ably total PSA in female serum (Borchert et al, 1997a; Ferguson et
al, 1996; Witherspoon and Lapeyrolerie, 1997). The PSA concen-
tration in female serum is very low and in the range of the lower
limit of detection of the currently available PSA assay systems.
Any differences that may be attributable to limitations of the sensi-
tivity of the PSA assays remain undetected.
The representative patient and control groups of the present
study consisted of 284 women, who were randomly selected from
a prospective, still ongoing case–control study with the participa-
tion of 2500 women. The clinical data were collected from well-
defined patient files of 90 women with histologically confirmed
breast cancer (BC) without any other malignancy, 94 women with
benign breast disease (BBD) and 100 healthy women (population
controls) and the population controls were matched with the BC
patients for age and long-term place of residence.
Our results show that a cut-off level of over 30 ng l–1 in total
PSA values was exceeded in 4.0% of the healthy controls, 3.2% of
the BBD patients and 5.6% of the BC, these differences between
the groups not being statistically significant. This does not agree
with a recent report, in which the percentage of female blood
donors (representing normal women) with PSA > 30 ng l–1 was
significantly lower than the percentage of BC or BBD (Borchert et
al, 1997b), and with another report, in which the percentage of
female blood donors between 17 and 69 years of age (representing
normal women) with PSA > 30 ng l–1 was significantly lower than
the percentage of BC patients aged between 29 and 93 before and
post surgery (Giai et al, 1995). The recent observation that serum
total PSA levels in patients with ductal carcinoma in situ are
higher than in patients with ductal carcinoma or other types of
breast carcinoma and in serum of patients with poorly differen-
tiated carcinomas (grade 3) compared with grade 1 or 2 tumours
(Borchert et al, 1997b) also remained unconfirmed since high total
PSA levels bore no relation to the clinical status of BC patients in
this present study. Total PSA median in our healthy controls
was 4 ng l–1, which is slightly higher than the total PSA median
(2.0 ng l–1) reported in a group of female blood donors in a
previous study (Borchert et al, 1997b). In our study, the total PSA
median in the group of BC patients was 5 ng l–1, which is also
higher than the median value (1.8 ng l–1) reported by Borchert
et al. These differences in medians may be due to differences in
standardization of the total PSA assays.
Exceptionally high serum PSA levels have been reported in
women with fibroadenomas and breast cysts (Borchert et al,
1997a). In another study, women with BBD (n = 199) had signifi-
cantly higher serum total PSA levels than female blood donors
(n = 213) or cancer patients (n = 199) (Borchert et al, 1997b). In
the present study material, one patient with fibroadenoma had PSA
levels in the range of males with prostate cancer. The patient was
receiving oestrogen replacement therapy, which is interesting in
light of reports suggesting that there is hormonal regulation of
PSA (Yu et al, 1995b; Zarghami et al, 1997). In the present study,
elevation of total PSA was detected only in 7% of the fibro-
adenoma and in none of the mastopathy patients. This shows that
elevated serum total PSA levels are not a consistent finding in
patients with benign breast disease, which is in accordance with a
previous report (Filella et al, 1996). The discrepancies between
these results and previous findings (Borchert et al, 1997a, 1997b)
may be due to the selection of the patients, differences in the
normal control groups (e.g. population controls in our
case–control study vs female blood donors in previous studies)
and/or our slightly less sensitive assay system.
Total PSA levels decrease with age in normal controls and
breast cancer patients but not in those with benign breast disease.
Additionally, total PSA levels were significantly higher in
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Table 3 Characteristics of the individual control persons (Co) and benign breast disease (BBD) and breast cancer (BC) patients with total PSA > 24 ng l–1 in
serum
Co 1 Co 2 Co 3 Co 4 Co 5 BBD 1 BBD 2 BBD 3 BC 1 BC 2 BC 3 BC 4 BC 5 BC 6
Diagnosisa (F) (F) (F) (DC) (DC) (LC) (DC) (DC) (DC)
Total PSAb 50 47 76 30 83 > 20 000 110 80 422 85 140 77 28 40
Age 60.0 53.2 67.5 39.8 41.0 44.5 31.4 42.1 53.3 50.1 55.4 33.3 48.7 55.5
Menopausal status Post Post Post Pre Pre Post Pre Post Post Post Pre Pre Pre Post
ERTc No No No No No Yes No No No No No No No Yes
ER/PRd ?/? –/– +/– –/+ –/+ ?/?
TNM T1N0M0 T4N2M1 T3N1M0 T2N1M0 T3N0M0 T1N0M0
Stage I IV III II III I
Grade III III III II II I
aDiagnosis (M), (F), (O), (DC) and (LC) as in Table 1. bTotal PSA (ng l–1). cERT = oestrogen replacement therapy. dER/PR = oestrogen/progesterone
receptor status; positive (+), negative (–) or unknown (?).premenopausal women than in post-menopausal ones in the
control group, but not in the BC and BBD patients. These findings
may be further indications that PSA is a marker of steroid hormone
action in normal breast (Yu et al, 1995b), but the response is
weaker in BC and virtually absent in BBD tissue or that the
leakage of PSA out of diseased breast tissue may be higher than
from normal breast tissue.
The combined evidence demonstrates that a single measurement
of the serum concentration of PSA in women detects high PSA
values in healthy women and female patients with both benign and
malignant breast disease. Thus, the total PSA concentration in
serum cannot distinguish between healthy women and/or women
with BC or BBD
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